Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
- Associated Therapies
- -
Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
- Conditions
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28000
- Registration Number
- NCT02792335
Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
- Conditions
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 14201
- Registration Number
- NCT02769078
Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
- Conditions
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 321182
- Registration Number
- NCT02754154
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
- Conditions
- Interventions
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 159
- Registration Number
- NCT02746185
- Locations
- 🇫🇷
CHU Amiens - Medecine vasculaire (003), Amiens, France
🇫🇷CHU Saint Etienne - Medecin vasculaire et therapeutique (006), Saint Etienne, France
🇫🇷Institut Curie - Soins de support en Cancerologie (020), Paris, France
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 811
- Registration Number
- NCT02744092
- Locations
- 🇺🇸
Washington Hospital, Fremont, California, United States
🇺🇸Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸Saint Joseph's Medical Center, Stockton, California, United States
Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Walter Ageno
- Target Recruit Count
- 1100
- Registration Number
- NCT02722447
- Locations
- 🇮🇹
Ospedale di Faenza, Faenza, Italy
🇮🇹Ospedale di Padova, Padua, Italy
🇮🇹Ospedale di Pieve di Soligo, Pieve di Soligo, Italy
Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- Hospital do Servidor Publico Estadual
- Target Recruit Count
- 84
- Registration Number
- NCT02704598
- Locations
- 🇧🇷
Hospital do Servidor Público Estadual de São Paulo, São Paulo, SP, Brazil
Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 3672
- Registration Number
- NCT02666157
- Locations
- 🇨🇳
E-DA Hospital, Kaohsiung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Tainan City, Taiwan
🇨🇳Tainan Hospital Ministry of Health and Welfare, Tainan, Tainan City, Taiwan
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
- Conditions
- Interventions
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2022-10-19
- Target Recruit Count
- 203
- Registration Number
- NCT02664155
- Locations
- 🇫🇷
CHU Toulouse, Toulouse 9, France
🇫🇷CH de Valenciennes, Valenciennes, France
🇫🇷CH ARRAS, Arras, Boulevard Georges Besnier, France
Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2016-05-25
- Target Recruit Count
- 12
- Registration Number
- NCT02657512
- Locations
- 🇫🇷
CHU de SAINT-ETIENNE, Saint-etienne, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.